Press release
Intrahepatic Cholangiocarcinoma Clinical Trials 2023 (Updates): FDA Approvals, Therapies, Treatment Market and Key Companies by DelveInsight | Basilea Pharmaceutica, AstraZeneca, Delcath Systems Inc., Syndax Pharmaceuticals, Medivir, Newish Technology (Be
Intrahepatic Cholangiocarcinoma Pipeline
To know more about the Intrahepatic Cholangiocarcinoma pipeline report offerings, click here @ https://www.delveinsight.com/report-store/intrahepatic-cholangiocarcinoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Some facts of the Intrahepatic Cholangiocarcinoma Pipeline Report
• DelveInsight's Intrahepatic Cholangiocarcinoma Pipeline analysis depicts a robust space with 20+ active players working to develop 20+ pipeline therapies for Intrahepatic Cholangiocarcinoma treatment.
• The leading Intrahepatic Cholangiocarcinoma companies include Basilea Pharmaceutica, AstraZeneca, Delcath Systems Inc., Jiangsu HengRui Medicine Co., Ltd., Syndax Pharmaceuticals, Hutchison Medipharma Limited, Medivir, Newish Technology (Beijing) Co., Ltd., Relay Therapeutics, Inc., Exelixis, Forma Therapeutics, Inc., Xencor, Inc., Zymeworks, RedHill Biopharma Limited, Genoscience Pharma, Kinnate Biopharma, Taiho Oncology, Inc., Sirtex Medical, Virogin Biotech Ltd, TriSalus Life Sciences, Tyra Biosciences, Siranomics, Instylla, Inc., and others are evaluating their lead assets to improve the Intrahepatic Cholangiocarcinoma treatment landscape.
• Key Intrahepatic Cholangiocarcinoma pipeline therapies in various stages of development include Derazantinib, VG161, SD 101, FT-2102, KIN-3248, RLY-4008, TYR-200, HMPL-453, Opaganib, XmAb®22841, STP705, Camrelizumab, Embrace™ Hydrogel Embolic System, CTX-009, and others.
• In February 2022, HUTCHMED initiated a Phase Ib/II Study of HMPL-453 in Combination with Chemotherapy or Toripalimab for Advanced Solid Tumors, including intrahepatic cholangiocarcinoma in China. HMPL-453 is also being evaluated as monotherapy in Phase II clinical trials in China.
• In 2022, Basilea will continue its oncology activities to ensure project continuity and progression. For derazantinib, the company will continue the FIDES-01 study in intrahepatic cholangiocarcinoma (iCCA).
• In January 2022, US FDA cleared the Investigational New Drug (IND) application for KIN-3248 being developed by Kinnate Biopharma. KIN-3248 is a next-generation pan-FGFR inhibitor being developed for intrahepatic cholangiocarcinoma.
Request a sample and discover the recent breakthroughs happening in the Intrahepatic Cholangiocarcinoma pipeline landscape @ https://www.delveinsight.com/sample-request/intrahepatic-cholangiocarcinoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Intrahepatic Cholangiocarcinoma Overview
Intrahepatic Cholangiocarcinoma (ICC), also known as Intrahepatic Bile Duct Cancer, is a type of cancer that develops in the liver's bile ducts. Intrahepatic Cholangiocarcinoma (ICC) is a relatively uncommon disease that accounts for approximately 10% of all cholangiocarcinomas. The 5-year survival rate for Intrahepatic Cholangiocarcinoma is 9%. The American Joint Committee on Cancer (AJCC) TNM staging method, which is now in its seventh edition and consists of four stages, is the most commonly used categorization system to evaluate the progression and resectability of Intrahepatic Cholangiocarcinoma. There was no separate Intrahepatic Cholangiocarcinoma staging method prior to this edition, and these tumors were classified as HCC.
Jaundice, abdominal pain, dark urine, clay-colored stool, fever, and itchy skin are the most common Intrahepatic Cholangiocarcinoma symptoms. Intrahepatic Cholangiocarcinoma is typically diagnosed when the tumor is unresectable due to locally advanced or metastatic disease. A liver mass, with or without biliary tract dilatation, is frequently detected using transabdominal ultrasound as the first imaging modality. Despite high recurrence rates of up to 80%, surgical excision is the only treatment option for Intrahepatic Cholangiocarcinoma. Intrahepatic recurrences may still be treated with curative intent in a small number of patients.
Find out more about Intrahepatic Cholangiocarcinoma medication @ https://www.delveinsight.com/sample-request/intrahepatic-cholangiocarcinoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Intrahepatic Cholangiocarcinoma Drug Analysis
Derazantinib: Basilea Pharmaceutica
Derazantinib is a small molecule inhibitor of the fibroblast growth factor receptor (FGFR) family of kinases that are taken orally. Derazantinib is currently being studied in phase II registrational study for intrahepatic cholangiocarcinoma (iCCA). Basilea released preliminary findings from this study in January 2019. The efficacy results were encouraging, and the analysis also confirmed derazantinib's safety profile and tolerability observed in previous clinical studies.
Durvalumab: AstraZeneca
Durvalumab is a human immunoglobulin G1 kappa (IgG1) monoclonal antibody that acts as a novel immune-checkpoint inhibitor in the treatment of cancer. Durvalumab, a programmed death-ligand 1 (PD-L1) blocking antibody produced by recombinant DNA technology in Chinese Hamster Ov@ry (CHO) cell suspension culture, works to promote normal immune responses that attack tumor cells.
Intrahepatic Cholangiocarcinoma Pipeline Therapies and Key Companies
• Derazantinib: Basilea Pharmaceutica
• VG161: Virogin Biotech Ltd
• SD 101: TriSalus Life Sciences
• FT-2102: Forma Therapeutics, Inc.
• KIN-3248: Kinnate Biopharma
• RLY-4008: Relay Therapeutics
Learn more about the novel and emerging Intrahepatic Cholangiocarcinoma pipeline therapies @ https://www.delveinsight.com/sample-request/intrahepatic-cholangiocarcinoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Scope of the Intrahepatic Cholangiocarcinoma Pipeline Report
• Coverage: Global
• Key Intrahepatic Cholangiocarcinoma Companies: Basilea Pharmaceutica, AstraZeneca, Delcath Systems Inc., Jiangsu HengRui Medicine Co., Ltd., Syndax Pharmaceuticals, Hutchison Medipharma Limited, Medivir, Newish Technology (Beijing) Co., Ltd., Relay Therapeutics, Inc., Exelixis, Forma Therapeutics, Inc., Xencor, Inc., Zymeworks, RedHill Biopharma Limited, Genoscience Pharma, Kinnate Biopharma, Taiho Oncology, Inc., Sirtex Medical, Virogin Biotech Ltd, TriSalus Life Sciences, Tyra Biosciences, Siranomics, Instylla, Inc., and others.
• Key Intrahepatic Cholangiocarcinoma Pipeline Therapies: Derazantinib, VG161, SD 101, FT-2102, KIN-3248, RLY-4008, TYR-200, HMPL-453, Opaganib, XmAb®22841, STP705, Camrelizumab, Embrace™ Hydrogel Embolic System, CTX-009, and others.
Dive deep into rich insights for drugs used for Intrahepatic Cholangiocarcinoma treatment; visit @ https://www.delveinsight.com/sample-request/intrahepatic-cholangiocarcinoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Table of Contents
1. Introduction
2. Executive Summary
3. Intrahepatic Cholangiocarcinoma Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Intrahepatic Cholangiocarcinoma Pipeline Therapeutics
6. Intrahepatic Cholangiocarcinoma Pipeline: Late Stage Products (Phase III)
7. Intrahepatic Cholangiocarcinoma Pipeline: Late Stage Products (Phase III)
8. Intrahepatic Cholangiocarcinoma Pipeline: Mid Stage Products (Phase II)
9. Intrahepatic Cholangiocarcinoma Pipeline: Early Stage Products (Phase I)
10. Intrahepatic Cholangiocarcinoma Therapeutic Assessment
11. Inactive Intrahepatic Cholangiocarcinoma Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Key Intrahepatic Cholangiocarcinoma Companies
14. Key Intrahepatic Cholangiocarcinoma Products
15. Intrahepatic Cholangiocarcinoma Unmet Needs
16. Intrahepatic Cholangiocarcinoma Market Drivers and Barriers
17. Future Perspectives and Conclusion
18. Analyst Views
19. Appendix
For further information on the Intrahepatic Cholangiocarcinoma therapy in the pipeline, reach out @ https://www.delveinsight.com/sample-request/intrahepatic-cholangiocarcinoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Trending Reports:
• Menorrhalgia Market - https://www.delveinsight.com/report-store/menorrhalgia-market
• Complicated Intra-Abdominal Infections market - https://www.delveinsight.com/report-store/complicated-intra-abdominal-infections-market
• Bronchial Spasm Market - https://www.delveinsight.com/report-store/bronchial-spasm-market
• Acute Radiation Syndrome Market - https://www.delveinsight.com/report-store/acute-radiation-syndrome-market
• Age Related Vision Dysfunction Market - https://www.delveinsight.com/report-store/age-related-vision-dysfunction-market
• Cerebral Aneurysm Market - https://www.delveinsight.com/report-store/cerebral-aneurysm-market
• Severe Hypoglycemia Market - https://www.delveinsight.com/report-store/severe-hypoglycemia-market
• Ada-Scid Competitive Landscape - https://www.delveinsight.com/report-store/ada-scid-competitive-landscape-and-market-insight
Contact Us:
Ankit Nigam
info@delveinsight.com
+1(919)321-6187
https://www.delveinsight.com/consulting
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end-to-end comprehensive solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Intrahepatic Cholangiocarcinoma Clinical Trials 2023 (Updates): FDA Approvals, Therapies, Treatment Market and Key Companies by DelveInsight | Basilea Pharmaceutica, AstraZeneca, Delcath Systems Inc., Syndax Pharmaceuticals, Medivir, Newish Technology (Be here
News-ID: 3008087 • Views: …
More Releases from DelveInsight Business Research
Niemann-Pick Type C Pipeline Report Showcases Emerging Drugs and Leading Compani …
DelveInsight's, "Niemann Pick C Disease Pipeline Insight, 2025" report provides comprehensive insights about 10+ companies and 15+ pipeline drugs in Niemann Pick C Disease pipeline landscape. It covers the Niemann-Pick Type C pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Niemann-Pick Type C pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this…
Pemphigus Vulgaris Market Positioned for Accelerated Development Through 2034, D …
DelveInsight's "Pemphigus Vulgaris Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Pemphigus Vulgaris, historical and forecasted epidemiology as well as the Pemphigus Vulgaris market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Pemphigus Vulgaris market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Pemphigus Vulgaris Market Forecast
https://www.delveinsight.com/sample-request/pemphigus-vulgaris-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the…
Osteogenesis Imperfecta Market to Evolve Rapidly Over the Next Decade by 2034, D …
The Osteogenesis Imperfecta market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Osteogenesis Imperfecta pipeline products will significantly revolutionize the Osteogenesis Imperfecta market dynamics.
DelveInsight's "Osteogenesis Imperfecta Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Osteogenesis Imperfecta, historical and forecasted epidemiology as well as the Osteogenesis Imperfecta market trends in the United…
Myopic Macular Degeneration Market Insights Highlight Expanding Outlook Till 203 …
DelveInsight's "Myopic Macular Degeneration Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Myopic Macular Degeneration, historical and forecasted epidemiology as well as the Myopic Macular Degeneration market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
The latest healthcare forecast report provides an in-depth analysis of Myopic Macular Degeneration, offering comprehensive insights into the Myopic Macular Degeneration revenue trends,…
More Releases for Intrahepatic
Progressive Familial Intrahepatic Cholestasis (PFIC) Market Growth, Trends, Cons …
Introduction
Progressive Familial Intrahepatic Cholestasis (PFIC) is a group of rare, inherited liver disorders characterized by defective bile secretion, leading to chronic cholestasis, liver damage, and progressive liver failure. PFIC typically manifests in infancy or early childhood and, without intervention, often requires liver transplantation at a young age.
For decades, treatment options were limited to symptomatic relief and surgical interventions. However, with the approval of bile acid transporter inhibitors, alongside the emergence…
Intrahepatic Cholangiocarcinoma Market is expected to reach USD 1.34 billion by …
Intrahepatic cholangiocarcinoma (iCCA) is a rare and aggressive form of bile duct cancer originating within the liver. It accounts for approximately 10-15% of primary liver cancers but has one of the poorest prognoses due to late-stage diagnosis and limited treatment options. Over recent years, genomic profiling has identified actionable mutations-including FGFR2 fusions, IDH1 mutations, and BRAF mutations-leading to the approval of targeted therapies and expanding treatment possibilities.
The iCCA market is…
Intrahepatic Cholangiocarcinoma Pipeline Insight 2025: 20+ Emerging Therapies Ta …
ChatGPT said: The intrahepatic cholangiocarcinoma (iCCA) pipeline is growing steadily, with over 18 companies focused on targeted and immunotherapeutic strategies. Key advances include FGFR2 fusions, IDH1/2 mutations, and HER2 amplifications, driving precision oncology in this aggressive liver cancer. Approvals of FGFR inhibitors like Pemazyre and Truseltiq have advanced biomarker-driven second-line treatments.
DelveInsight's "Intrahepatic Cholangiocarcinoma - Pipeline Insight, 2025 [https://www.delveinsight.com/report-store/intrahepatic-cholangiocarcinoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=jpr]" provides a detailed analysis of the therapeutic development landscape for iCCA, a…
Intrahepatic Cholangiocarcinoma Market Generated Opportunities, Future Scope 202 …
The intrahepatic cholangiocarcinoma market is estimated to be valued at USD 1.10 billion in 2025 and is expected to reach USD 1.90 billion by 2032, growing at a compound annual growth rate (CAGR) of 8.1% from 2025 to 2032.
According to the latest research from CoherentMI, the Intrahepatic Cholangiocarcinoma Market is projected to experience significant growth between 2025 and 2032. This market intelligence report offers in-depth analysis based on thorough…
Progressive Familial Intrahepatic Cholestasis Pipeline: Promising Therapies Shap …
The treatment landscape for Progressive Familial Intrahepatic Cholestasis (PFIC), a rare and progressive liver disorder, is evolving rapidly, driven by innovative therapies from leading pharmaceutical and biotech companies. Key players such as Mirum Pharmaceuticals and Vivet Therapeutics are advancing therapeutic options focused on addressing the root causes of cholestasis, including bile acid regulation and hepatic transport. These emerging treatments aim to improve liver function, reduce pruritus, and delay the progression…
Transjugular Intrahepatic Portosystemic Shunt (TIPS) Boston Scientific Corporati …
Transjugular Intrahepatic Portosystemic Shunt (TIPS) is a minimally invasive procedure used to treat complications of portal hypertension, such as variceal bleeding and refractory ascites. It involves creating a shunt between the portal and hepatic veins, bypassing the liver to reduce portal pressure. TIPS is performed under fluoroscopic guidance by interventional radiologists. It effectively alleviates symptoms and reduces the risk of complications associated with portal hypertension. TIPS is typically reserved for…
